LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 8 of 15: Cell count and normalized growth rate inhibition values within biological replicate 1. - Dataset (ID:20245)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Tozasertib | 1.11 | uM | LJP5 | 3 | B15 | 72 | hr | 1476 | 1295 | 3796 | 0.3411 | -0.0919 |
| SK-BR-3 | Tozasertib | 3.33 | uM | LJP5 | 1 | B14 | 72 | hr | 1476 | 1277 | 3788 | 0.3371 | -0.1014 |
| SK-BR-3 | Tozasertib | 3.33 | uM | LJP5 | 2 | B14 | 72 | hr | 1476 | 1309 | 3731 | 0.3508 | -0.0862 |
| SK-BR-3 | Tozasertib | 3.33 | uM | LJP5 | 3 | B14 | 72 | hr | 1476 | 1292 | 3796 | 0.3403 | -0.0934 |
| SK-BR-3 | Tozasertib | 10 | uM | LJP5 | 1 | B13 | 72 | hr | 1476 | 1253 | 3788 | 0.3307 | -0.1138 |
| SK-BR-3 | Tozasertib | 10 | uM | LJP5 | 2 | B13 | 72 | hr | 1476 | 1415 | 3731 | 0.3792 | -0.0314 |
| SK-BR-3 | Tozasertib | 10 | uM | LJP5 | 3 | B13 | 72 | hr | 1476 | 1316 | 3796 | 0.3466 | -0.0811 |
| SK-BR-3 | Imatinib | 0.04 | uM | LJP6 | 1 | N18 | 72 | hr | 1476 | 3274 | 3413 | 0.9592 | 0.9322 |
| SK-BR-3 | Imatinib | 0.04 | uM | LJP6 | 2 | N18 | 72 | hr | 1476 | 3868 | 3783 | 1.0223 | 1.0328 |
| SK-BR-3 | Imatinib | 0.04 | uM | LJP6 | 3 | N18 | 72 | hr | 1476 | 3826 | 3734 | 1.0246 | 1.0367 |
| SK-BR-3 | Imatinib | 0.12 | uM | LJP6 | 1 | N17 | 72 | hr | 1476 | 3499 | 3413 | 1.0251 | 1.0415 |
| SK-BR-3 | Imatinib | 0.12 | uM | LJP6 | 2 | N17 | 72 | hr | 1476 | 4034 | 3783 | 1.0662 | 1.0967 |
| SK-BR-3 | Imatinib | 0.12 | uM | LJP6 | 3 | N17 | 72 | hr | 1476 | 3992 | 3734 | 1.0691 | 1.1023 |
| SK-BR-3 | Imatinib | 0.37 | uM | LJP6 | 1 | N16 | 72 | hr | 1476 | 3313 | 3413 | 0.9706 | 0.9513 |
| SK-BR-3 | Imatinib | 0.37 | uM | LJP6 | 2 | N16 | 72 | hr | 1476 | 3967 | 3783 | 1.0485 | 1.0710 |
| SK-BR-3 | Imatinib | 0.37 | uM | LJP6 | 3 | N16 | 72 | hr | 1476 | 3954 | 3734 | 1.0589 | 1.0874 |
| SK-BR-3 | Imatinib | 1.11 | uM | LJP6 | 1 | N15 | 72 | hr | 1476 | 3818 | 3413 | 1.1186 | 1.1943 |
| SK-BR-3 | Imatinib | 1.11 | uM | LJP6 | 2 | N15 | 72 | hr | 1476 | 3649 | 3783 | 0.9645 | 0.9474 |
| SK-BR-3 | Imatinib | 1.11 | uM | LJP6 | 3 | N15 | 72 | hr | 1476 | 3965 | 3734 | 1.0618 | 1.0917 |
| SK-BR-3 | Imatinib | 3.33 | uM | LJP6 | 1 | N14 | 72 | hr | 1476 | 3868 | 3413 | 1.1332 | 1.2180 |
| SK-BR-3 | Imatinib | 3.33 | uM | LJP6 | 2 | N14 | 72 | hr | 1476 | 4387 | 3783 | 1.1595 | 1.2304 |
| SK-BR-3 | Imatinib | 3.33 | uM | LJP6 | 3 | N14 | 72 | hr | 1476 | 4022 | 3734 | 1.0771 | 1.1141 |
| SK-BR-3 | Imatinib | 10 | uM | LJP6 | 1 | N13 | 72 | hr | 1476 | 3396 | 3413 | 0.9949 | 0.9916 |
| SK-BR-3 | Imatinib | 10 | uM | LJP6 | 2 | N13 | 72 | hr | 1476 | 3812 | 3783 | 1.0075 | 1.0111 |
| SK-BR-3 | Imatinib | 10 | uM | LJP6 | 3 | N13 | 72 | hr | 1476 | 3761 | 3734 | 1.0072 | 1.0108 |